Key Points
- Director sale: Bernadette Connaughton sold 1,626 Halozyme shares for $167,152.80 at an average price of $102.80 under a pre-arranged Rule 10b5-1 plan, reducing her holdings by 3.87% to 40,418 shares.
- Strong quarterly results: Halozyme reported $2.28 in quarterly EPS versus the $1.79 analyst consensus, while revenue rose 47.7% year over year to $481 million. The company issued fiscal 2026 EPS guidance of $8.65–$9.00.
- Positive analyst sentiment: Analysts maintain a consensus “Moderate Buy” rating, with nine Buy, three Hold and one Sell rating; recent price targets increased as high as $115, compared with a consensus target of $91.20.
Halozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) Director Bernadette Connaughton sold 1,626 shares of Halozyme Therapeutics stock in a transaction on Monday, August 10th. The shares were sold at an average price of $102.80, for a total value of $167,152.80. Following the transaction, the director owned 40,418 shares in the company, valued at $4,154,970.40. This represents a 3.87% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Bernadette Connaughton also recently made the following trade(s):
- On Wednesday, July 1st, Bernadette Connaughton sold 1,625 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $76.71, for a total value of $124,653.75.
- On Monday, June 1st, Bernadette Connaughton sold 1,625 shares of Halozyme Therapeutics stock. The stock was sold at an average price of $66.21, for a total value of $107,591.25.
Halozyme Therapeutics Stock Performance
NASDAQ:HALO opened at $102.62 on Wednesday. The stock's 50-day moving average is $77.89 and its two-hundred day moving average is $71.92. The company has a debt-to-equity ratio of 13.50, a current ratio of 2.71 and a quick ratio of 2.31. The stock has a market cap of $11.65 billion, a PE ratio of 30.63, a price-to-earnings-growth ratio of 0.43 and a beta of 0.85. Halozyme Therapeutics, Inc. has a fifty-two week low of $61.22 and a fifty-two week high of $104.78.
Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The company had revenue of $481.00 million during the quarter, compared to the consensus estimate of $402.28 million. During the same quarter in the prior year, the firm earned $1.54 EPS. The company's revenue was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, equities research analysts forecast that Halozyme Therapeutics, Inc. will post 7.54 earnings per share for the current fiscal year.
Institutional Trading of Halozyme Therapeutics
A number of institutional investors and hedge funds have recently modified their holdings of HALO. Measured Wealth Private Client Group LLC boosted its holdings in shares of Halozyme Therapeutics by 51.5% during the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 124 shares during the period. Larson Financial Group LLC raised its holdings in Halozyme Therapeutics by 3,118.2% in the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 343 shares during the period. MidFirst Bank bought a new position in Halozyme Therapeutics in the 2nd quarter worth $27,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in Halozyme Therapeutics during the 2nd quarter worth $28,000. Finally, Harbour Investments Inc. lifted its position in Halozyme Therapeutics by 152.5% during the 4th quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company's stock worth $41,000 after acquiring an additional 372 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
HALO has been the subject of several recent research reports. Benchmark reissued a "buy" rating on shares of Halozyme Therapeutics in a research report on Tuesday, July 21st. Wall Street Zen upgraded shares of Halozyme Therapeutics from a "buy" rating to a "strong-buy" rating in a report on Saturday. Leerink Partners raised shares of Halozyme Therapeutics from a "market perform" rating to an "outperform" rating and lifted their price objective for the company from $83.00 to $110.00 in a research note on Friday, August 7th. UBS Group reaffirmed a "buy" rating and issued a $90.00 price target on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Finally, HC Wainwright upped their price target on Halozyme Therapeutics from $95.00 to $115.00 and gave the stock a "buy" rating in a research note on Friday, August 7th. Nine research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $91.20.
Read Our Latest Report on HALO
About Halozyme Therapeutics
(
Get Free Report)
Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.
The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
